Leaderboards/Gastric Cancer Management and Outcomes

Gastric Cancer Management and Outcomes

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Mohit Sodhi
University of British Columbia
2
Y.L. Verschoor
Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
3
Arjen van der Veen
University Medical Center Utrecht
4
Veronika Engelsberger
Institute of Medical Microbiology and Hygiene
5
Jacobi Hines
Northwestern University
6
A. Vogel
Princess Margaret Cancer Centre
7
Leilani Lakemeyer
University Hospital Ulm
8
Antonio Pellino
Ospedale di Livorno
9
Konrad Lehr
Friedrich-Alexander-Universität Erlangen-Nürnberg
10
Liwei Du
Chinese Academy of Medical Sciences & Peking Union Medical College

Papers

1
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Nature Medicine|2024
107 cit.
2
Effects of Helicobacter pylori infection on intestinal microbiota, immunity and colorectal cancer risk
Frontiers in Cellular and Infection Microbiology|2024
81 cit.
3
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC
Journal of Thoracic Oncology|2024
74 cit.
4
Publication in ESMO Open (2024) [70 citations, W4405475772]
ESMO Open|2024
70 cit.
5
Publication in Scientific Reports (2024) [10 citations, W4400274377]
Scientific Reports|2024
10 cit.
6
Publication in mSystems (2025) [10 citations, W4406906287]
mSystems|2025
10 cit.
7
Publication in Annals of Oncology (2024) [3 citations, W4402561806]
Annals of Oncology|2024
3 cit.
8
Publication in Zeitschrift für Gastroenterologie (2024) [W4403057781]
Zeitschrift für Gastroenterologie|2024
0 cit.
9
Publication in Gastroenterology (2025) [W4411999879]
Gastroenterology|2025
0 cit.
10
Publication in Zeitschrift für Gastroenterologie (2025) [W4414041587]
Zeitschrift für Gastroenterologie|2025
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Lenora A. Pluchino
National Comprehensive Cancer Network
2
Elizabeth Smyth
National Health Service
3
Chao‐Hui Zheng
Fujian Medical University
4
Deborah A. Freedman-Cass
Unknown
5
Ina Felau
National Cancer Institute
6
Walid K. Chatila
Memorial Sloan Kettering Cancer Center
7
Karla Kopp
Mayo Clinic in Arizona
8
John A. Demchok
National Cancer Institute
9
Natália D. Aredes
Universidade Federal de Goiás
10
Michelle Bellair
Lunar and Planetary Institute

Papers

1
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2022
1.7k cit.
2
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology|2022
1.4k cit.
3
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology|2022
656 cit.
4
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2023
520 cit.
5
Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
Nature Medicine|2022
149 cit.
6
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
ESMO Open|2024
90 cit.
7
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022
Journal of the National Comprehensive Cancer Network|2022
76 cit.
8
Integrated clinical and genomic analysis identifies driver events and molecular evolution of colitis-associated cancers
Nature Communications|2023
51 cit.
9
Prognostic impact of lymphovascular and perineural invasion in squamous cell carcinoma of the tongue
Scientific Reports|2023
34 cit.
10
Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
PubMed|2022
32 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Sung Hoon Noh
Gangnam Severance Hospital
2
Mitsuru Sasako
Yodogawa Christian Hospital
3
Kazuaki Chayama
RIKEN Center for Integrative Medical Sciences
4
Ahmedin Jemal
American Cancer Society
5
Michael J. Bourke
The University of Sydney
6
Dirk Arnold
Asklepios Klinik Altona
7
Douglas K. Rex
Indiana University School of Medicine
8
Rui‐Hua Xu
Sun Yat-sen University
9
Han‐Kwang Yang
Cancer Research Institute
10
Jaffer A. Ajani
The University of Texas MD Anderson Cancer Center

Papers

1
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA A Cancer Journal for Clinicians|2018
87.7k cit.
2
Global cancer statistics
CA A Cancer Journal for Clinicians|2011
55k cit.
3
Global cancer statistics, 2012
CA A Cancer Journal for Clinicians|2015
27.4k cit.
4
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
CA A Cancer Journal for Clinicians|2024
23.1k cit.
5
Cancer statistics, 2020
CA A Cancer Journal for Clinicians|2020
21.4k cit.
6
Cancer statistics, 2019
CA A Cancer Journal for Clinicians|2019
21k cit.
7
Cancer statistics, 2022
CA A Cancer Journal for Clinicians|2022
18.2k cit.
8
Cancer Statistics, 2021
CA A Cancer Journal for Clinicians|2021
17.4k cit.
9
Cancer statistics, 2018
CA A Cancer Journal for Clinicians|2018
17k cit.
10
Cancer statistics, 2023
CA A Cancer Journal for Clinicians|2023
16.7k cit.

Reagents for Gastric Cancer Management and Outcomes

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

Cell Signaling TechnologyEvidence 68

OLFM4 (D1E4M) Rabbit Monoclonal Antibody

#14369$178,415
View Evidence →

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 65

Stat3 (D1B2J) Rabbit Monoclonal Antibody

Cited in 5 papers
#30835$167,366
View Evidence →
Cell Signaling TechnologyEvidence 66

VDAC Antibody

#4866$135,314
View Evidence →
Cell Signaling Technology

Total p21 Waf1/Cip1 Matched Antibody Pair

#24283$1,726
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 66

Rb (4H1) Mouse Monoclonal Antibody (BSA and Azide Free)

Cited in 6 papers
#61121$865
View Evidence →
Cell Signaling TechnologyEvidence 65

BAF Antibody

Cited in 6 papers
#62935$317
View Evidence →
RocheEvidence 75

VENTANA® anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody

Cited in 6 papers
#760-5095 (also 08033706001)
View Evidence →